ArticleJournal of Korean medical science2026
Complementary Roles of Next-Generation Flow and Next-Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHighly sensitive measurable residual disease (MRD) assays play a crucial role in predicting prognosis and guiding further treatment in multiple myeloma (MM). This study aimed to compare the diagnostic performance and clinical utility of next-generation flow (NGF)- and next-generation sequencing (NGS)-based MRD assays in patients with MM.
methodsWe evaluated 55 bone marrow (BM) aspirate samples from 41 MM patients for MRD. NGF-MRD was performed on fresh BM specimens in accordance with EuroFlow standard operating procedures, whereas NGS-MRD was conducted on archived BM DNA using the LymphoTrack
resultsThe MRD detection rates were 43.6% (24/55) for NGF-MRD and 29.1% (16/55) for NGS-MRD with 67.3% (37/55) concordance rate between two MRD assays, and correlation coefficient (
conclusionBoth NGF-MRD and NGS-MRD play critical and complementary roles in monitoring MRD in MM. Notably, even isolated MRD positivity detected by either method was associated with disease progression in certain cases, underscoring the importance of both MRD assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.